Subscribe to NRx Newsletter

RLF-100_002

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health

CISON PR Newswire RADNOR, Pa. and IRVINE, Calif., Feb. 3, 2021 /PRNewswire/ — NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine. UCI Health was also a key site in the recently-completed […]